

## FOR IMMEDIATE RELEASE

Contact: Julie Bryant  
VP Business Development and Marketing  
GeneGo, Inc.  
(858) 756 7996  
julie@genego.com

### GENEGO NAMES CHARLES R. CANTOR, Ph.D., TO SCIENTIFIC ADVISORY BOARD

**St. Joseph, Michigan**, December 15, 2003 — GeneGo today announced the appointment of Charles R. Cantor, Ph.D. to its Scientific Advisory Board. A world-renowned scientist, Dr. Cantor has authored over 360 peer reviewed articles, the first textbook on genomics *Genomics: The Science and Technology of the Human Genome Project*, co-authored a three volume textbook on Biophysical Chemistry, and been granted 54 patents.

“I’m pleased to serve on GeneGo’s scientific advisory board,” said Dr. Cantor. “GeneGo’s computational platform technology will enable researchers to integrate information from several sources and efficiently analyze it for a clearer understanding of disease mechanics.”

“We are delighted to welcome Dr. Cantor to our Scientific Advisory Board,” said Dr. Tatiana Nikolskaya, President of GeneGo. “His scientific expertise and industry name recognition will be a valuable addition as we develop new products and move into additional markets”.

Dr. Cantor is currently Chief Scientific Officer and a Board Director of SEQUENOM, Inc. He is also director of the Center for Advanced Biotechnology at Boston University. Dr. Cantor has held positions at Columbia University and University of California at Berkeley, and was director of the Human Genome Center of the Department of Energy at Lawrence Berkeley Laboratory. In 2002, he founded SelectX Pharmaceuticals.

#### About GeneGo

GeneGo is a Michigan-based company developing systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolites, phenotypic data, etc.) and relevant active chemistry (metabolites, drugs, other xenobiotics) within the framework of biological pathways and networks. GeneGo’s first product, MetaCore™, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. MetaCore™ integrates all levels of cellular functionality - from membrane receptors to signal transduction, transcription factors, and effector networks - and is based on the proprietary database of curated functional pathways and networks. Additional information about GeneGo and MetaCore™ is available at [www.genego.com](http://www.genego.com).

MetaCore™ and MetaDrug™ are the trademarks of GeneGo, Inc.